title: [Observations on the course of advanced ovarian cancers following medicamentous reduction of hypophyseal gonadotropins].
abstract: Previous observations in healthy women showed, that the increase of CA-125 observed during progression of ovarian cancer could be dependent on pituitary gonadotropins. Therefore, the GnRH-analog D-Trp 6-LH-RH was administered to 17 patients with progressive ovarian cancer and increasing CA-125 serum levels. 12 of 17 patients who had been treated for more than three months exhibited a considerably slower increase of CA-125 which was associated with a remarkable stabilisation of disease. The other patients, who suffered from progressive disease, an increase of the gonadotropins could be detected during the analog treatment. These observations strengthen the suspicion of the critical role of gonadotropins in the production of CA-125 and the progression of ovarian cancer.
authors.affiliation: Universitäts-Frauenklinik der Friedrich-Alexander-Universität Erlangen-Nürnberg.
authors.forename: W
authors.initials: W
authors.lastname: Jäger
authors.forename: L
authors.initials: L
authors.lastname: Wildt
authors.forename: N
authors.initials: N
authors.lastname: Lang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D017329:Triptorelin Pamoate
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D000970:Antineoplastic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
vernacular_title: Beobachtungen des Verlaufs fortgeschrittener Ovarialkarzinome nach medikamentöser Reduktion hypophysärer Gonadotropine.